Tagged with Biopharma

Ireland Una Halligan, Chairperson of the Expert Group on Future Skills Needs (EGFSN), outlines the findings of its recently published report on the biopharma industry, the advantages Ireland can offer the global biopharma industry, and her thoughts on the importance of open communication and collaboration between industry and the educational sector.…

Amgen Established in November 2014, Amgen’s Next-Generation Biomanufacturing facility in Singapore heralds a new juncture of efficient and innovative commercial-scale production of medicines. VP of Singapore Site Operations, Arleen Paulino, pinpoints the elements that distinguish this facility from current standards in manufacturing, while highlighting the key role that this facility will…

Singapore With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in Singapore and his experience in setting up the affiliate, while also expounding upon the unique value of Amgen products in…

Merck Asanga Halangoda, Director of Life Science at Merck Philippines, discusses the company’s impressive recent market performance, the importance of innovation in maintaining product pipeline, and the bright future of the affiliate’s role in the company’s emerging market portfolio. As an introduction to our readers, could you please give us an…

Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…

Pharma FDI into Irish pharma has almost exclusively targeted in biologics production over the last few years, largely due to Ireland’s skilled workforce of bioprocessing technicians. NIBRT director Dominic Carolan discusses how the institute supports the Irish biopharma industry through training and recruitment solutions, while pursuing research that may help to…

Pharma Merck Czech Republic’s MD reveals his plan to double Merck operations within the next five years and talks about the impact of the recent acquisition of Sigma Aldrich on the Czech Republic. You’ve assumed position as Managing Director Merck Czech Republic just over one year ago; what was the strategy…

Pharma Rafael Suarez, general manager of Ferring in Mexico, explains how the Swiss biopharmaceutical company is adapting to the recent dynamics affecting both the Mexican public and private sectors. He outlines his approach to further consolidate the Mexican affiliate, increase Ferring’s clinical research investments and manufacturing presence in Mexico. When Pharmaceutical…

Pharma As President of Biopharma Activities for Merck in France, Pierre-Henry Longeray reveals how France is the third ranked affiliate after the US and Germany for the Group; how the French culture of innovation is one of the main drivers of the business; and how Merck is shifting from a pharmaceutical…

Pharma The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic role that the subsidiary now plays in producing and distributing the company’s lifesaving biotherapies both inside and outside of Hungary.…

Pharma The GM of France for Bristol-Myers Squibb (BMS) discusses becoming a “diversified biopharma company”, their commitment to remaining a model of excellence for other affiliates, and his personal philosophy of leadership, moulded by two decades of international experience. You started off your term with a restructuring plan for the French…

Pharma Biopharmaceutical logistics leader World Courier strives to understand their clients’ needs as early as possible, and the Italian affiliate has gone to unusual lengths, including joining the Italian biotech association, to study the developments emerging at the industry level together with other stakeholders. What have been the main changes in…